Critical Updates on uniQure (QURE) Amidst FDA Controversy and Class Action Deadline Approaching
Recent Developments on uniQure (QURE)
In an alarming turn of events, shareholder rights law firm Hagens Berman has ramped up its investigation regarding uniQure N.V. (NASDAQ: QURE) following stern criticisms from the Food and Drug Administration (FDA). These criticisms specifically revolved around the company's lead gene therapy candidate, AMT-130, with the FDA branding it a "failed therapy" during press interactions.
The Background of the Issue
This investigation comes in light of a securities class-action lawsuit which aims to represent investors who acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025—now dubbed the
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.